Marin C, Chase T N
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892.
Eur J Pharmacol. 1993 Feb 9;231(2):191-6. doi: 10.1016/0014-2999(93)90448-q.
The effect of selective dopamine D1 and D2 receptor agonists on chronic haloperidol-treated rats was studied. Haloperidol treatment produced a 77% increase in apomorphine-induced sterotypy. The administration of the selective dopamine D1 receptor agonist SKF38393 alone or in combination with the selective dopamine D2 receptor agonist quinpirole attenuated the effect of haloperidol. Treatment with quinpirole alone did not have a significant effect on the response to haloperidol. Haloperidol did not modify the number of dopamine D1 receptors but increased that of dopamine D2 receptors. SKF38393 reversed the effect of haloperidol on dopamine D2 receptor binding. Co-administration of SKF38393 and quinpirole did not modify the increase in the number of dopamine D2 receptors induced by chronic treatment haloperidol. The results confirm a dissociation between behavioral supersensitivity and dopamine receptor up-regulation, suggesting that other mechanisms may be involved in the expression of behavioral supersensitivity.
研究了选择性多巴胺D1和D2受体激动剂对慢性氟哌啶醇治疗大鼠的影响。氟哌啶醇治疗使阿扑吗啡诱导的刻板行为增加了77%。单独给予选择性多巴胺D1受体激动剂SKF38393或与选择性多巴胺D2受体激动剂喹吡罗联合使用,均可减弱氟哌啶醇的作用。单独使用喹吡罗治疗对氟哌啶醇反应无显著影响。氟哌啶醇未改变多巴胺D1受体数量,但增加了多巴胺D2受体数量。SKF38393逆转了氟哌啶醇对多巴胺D2受体结合的影响。SKF38393和喹吡罗联合给药未改变慢性氟哌啶醇治疗诱导的多巴胺D2受体数量增加。结果证实了行为超敏反应与多巴胺受体上调之间的分离,提示行为超敏反应的表达可能涉及其他机制。